Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients

Leukemia

Volumn 25, Issue 1, 2011, Pages 82-88

  Caramazza, D ^a   Begna, K H ^b   Gangat, N ^b   Vaidya, R ^b   Siragusa, S ^a   Van Dyke, D L ^b   Hanson, C ^b   Pardanani, A ^b   Tefferi, A ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

cytogenetics; karyotype; myelofibrosis; myeloproliferative; prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 1; CHROMOSOME DUPLICATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 78651344350     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.234     Document Type: Article

References (28)

1. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
2. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
3. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22: 474-486.
4. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008; 22: 1790-1792.
5. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441-1445.
6. Tefferi A. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant 2010; 45: 419-421.
7. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloprolifera-tive disorders. Leukemia 2008; 22: 905-914.
8. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
9. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
10. Hidaka T, Shide K, Shimoda H, Kameda T, Toyama K, Katayose K et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol 2009; 83: 328-333.
11. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115: 496-499.
12. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009; 113: 4171-4178.
13. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. BrJ Haematol 2001; 113: 763-771.
14. Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S et al. Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4146.
15. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Press: Lyon, France, 2001, pp 17-44.
16. Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV. The efficacy of direct, 24-h culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985; 18: 1-10.
17. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
18. Shaffer LG, Slovak ML, Campbell LJ (eds). ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Karger: Basel, 2009.
19. Rumi E, Passamonti F, Bernasconi P, Arcaini L, Pietra D, Elena C et al. Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood 2010; 115: 2719-2720.
20. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109: 2083-2088.
21. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer2008; 112: 2726-2732.
22. Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythe-mia myelofibrosis. J Clin Oncol 2009; 27: 5587-5593.
23. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
24. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105-109.
25. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
26. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.
27. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood2009; 114: 1477-1483.
28. Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. BrJ Haematol 2007; 139: 265-268.